314 related articles for article (PubMed ID: 23536690)
1. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
[TBL] [Abstract][Full Text] [Related]
2. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
[TBL] [Abstract][Full Text] [Related]
4. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
[TBL] [Abstract][Full Text] [Related]
5. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
9. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
Bihari I; Pánczél G; Kovacs J; Beygo J; Fragapane E
Clin Vaccine Immunol; 2012 Dec; 19(12):1943-8. PubMed ID: 23081815
[TBL] [Abstract][Full Text] [Related]
10. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
Banzhoff A; Gasparini R; Laghi-Pasini F; Staniscia T; Durando P; Montomoli E; Capecchi PL; di Giovanni P; Sticchi L; Gentile C; Hilbert A; Brauer V; Tilman S; Podda A
PLoS One; 2009; 4(2):e4384. PubMed ID: 19197383
[TBL] [Abstract][Full Text] [Related]
11. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
Khurana S; Coyle EM; Dimitrova M; Castellino F; Nicholson K; Del Giudice G; Golding H
PLoS One; 2014; 9(4):e95496. PubMed ID: 24755693
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
Izurieta P; Uy-Aragon MJ; Dramé M; Vaughn DW
Pediatr Infect Dis J; 2016 Feb; 35(2):e35-47. PubMed ID: 26551446
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
15. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
16. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
17. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
[TBL] [Abstract][Full Text] [Related]
19. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.
Fragapane E; Gasparini R; Schioppa F; Laghi-Pasini F; Montomoli E; Banzhoff A
Clin Vaccine Immunol; 2010 Nov; 17(11):1817-9. PubMed ID: 20810680
[TBL] [Abstract][Full Text] [Related]
20. An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.
Gillard P; Caplanusi A; Knuf M; Roman F; Walravens K; Moris P; Dramé M; Schwarz TF
Influenza Other Respir Viruses; 2013 Jan; 7(1):55-65. PubMed ID: 22405557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
